TNSN05035A1 - Formes cristallines de [4-carbamoyl-1-(3-fluorobenzyl)-2, 7-dihydroxy-7-methyloctyl]-amide d'acide quinoxaline-2-carboxylique - Google Patents

Formes cristallines de [4-carbamoyl-1-(3-fluorobenzyl)-2, 7-dihydroxy-7-methyloctyl]-amide d'acide quinoxaline-2-carboxylique

Info

Publication number
TNSN05035A1
TNSN05035A1 TNP2005000035A TNSN05035A TNSN05035A1 TN SN05035 A1 TNSN05035 A1 TN SN05035A1 TN P2005000035 A TNP2005000035 A TN P2005000035A TN SN05035 A TNSN05035 A TN SN05035A TN SN05035 A1 TNSN05035 A1 TN SN05035A1
Authority
TN
Tunisia
Prior art keywords
fluorobenzyl
carbamoyl
dihydroxy
carboxylic acid
amide
Prior art date
Application number
TNP2005000035A
Other languages
English (en)
Inventor
John Charles Kath
Zheng Jane Li
Zhengong Bryan Li
Eric Brock Mcelroy
Clifford Nathaniel Meltz
Christopher Stanley Poss
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN05035A1 publication Critical patent/TNSN05035A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des formes cristallines de [4-carbamoyl-1-(3-fluorobenzyl)-2, 7-dihydroxy-7-méthyl-octyl]-amide d'acide quinoxaline-carboxylique, utiles dans le traitement ou la prévention d'un trouble ou d'une affection en antagonisant le récepteur CCR1, et les procédés pour leur préparation et leur utilisation.
TNP2005000035A 2002-08-12 2005-02-11 Formes cristallines de [4-carbamoyl-1-(3-fluorobenzyl)-2, 7-dihydroxy-7-methyloctyl]-amide d'acide quinoxaline-2-carboxylique TNSN05035A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40321602P 2002-08-12 2002-08-12
PCT/IB2003/003464 WO2004014875A1 (fr) 2002-08-12 2003-07-31 Formes cristallines d'acide quinoxaline-2-carboxylique [4-carbamoyl-1-(3-fluorobenzyl)-2,7-dihydroxy-7-methyl-octyl]-amide

Publications (1)

Publication Number Publication Date
TNSN05035A1 true TNSN05035A1 (fr) 2007-05-14

Family

ID=31715961

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2005000035A TNSN05035A1 (fr) 2002-08-12 2005-02-11 Formes cristallines de [4-carbamoyl-1-(3-fluorobenzyl)-2, 7-dihydroxy-7-methyloctyl]-amide d'acide quinoxaline-2-carboxylique

Country Status (22)

Country Link
US (1) US20040072834A1 (fr)
EP (1) EP1539715A1 (fr)
JP (1) JP2005538130A (fr)
AP (1) AP2005003226A0 (fr)
AR (1) AR040839A1 (fr)
AU (1) AU2003250450A1 (fr)
BR (1) BR0313378A (fr)
CA (1) CA2494776A1 (fr)
EC (1) ECSP055588A (fr)
GT (1) GT200300169A (fr)
IL (1) IL166548A0 (fr)
IS (1) IS7674A (fr)
MX (1) MXPA05001781A (fr)
NO (1) NO20050540L (fr)
OA (1) OA12894A (fr)
PA (1) PA8580401A1 (fr)
PE (1) PE20040866A1 (fr)
TN (1) TNSN05035A1 (fr)
TW (1) TW200407316A (fr)
UY (1) UY27928A1 (fr)
WO (1) WO2004014875A1 (fr)
ZA (1) ZA200500768B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201130810A (en) 2009-12-23 2011-09-16 Ironwood Pharmaceuticals Inc CRTH2 modulators
US20130259830A1 (en) 2010-07-12 2013-10-03 Ironwood Pharmaceuticals, Inc. Crth2 modulators
US20130216552A1 (en) 2010-07-12 2013-08-22 Ironwood Pharmaceuticals, Inc. Crth2 modulators
CN102276539B (zh) * 2011-06-29 2013-08-14 赵雪梅 一种具有抑菌作用的化合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (fr) * 1962-12-19
US3492397A (en) * 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) * 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) * 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
CN1248968A (zh) * 1997-02-26 2000-03-29 辉瑞大药厂 杂芳基－己酸酰胺衍生物、其制备方法及其作为MIP－1α与其CCRI受体结合的选择性抑制剂的用途
KR100385529B1 (ko) * 1998-02-05 2003-05-27 화이자 프로덕츠 인코포레이티드 신규 디하이드록시헥산산 유도체

Also Published As

Publication number Publication date
US20040072834A1 (en) 2004-04-15
AP2005003226A0 (en) 2005-03-31
AR040839A1 (es) 2005-04-20
MXPA05001781A (es) 2005-04-25
PA8580401A1 (es) 2004-02-16
IL166548A0 (en) 2006-01-15
UY27928A1 (es) 2004-03-31
OA12894A (en) 2006-10-13
NO20050540L (no) 2005-03-10
AU2003250450A1 (en) 2004-02-25
WO2004014875A1 (fr) 2004-02-19
TW200407316A (en) 2004-05-16
CA2494776A1 (fr) 2004-02-19
JP2005538130A (ja) 2005-12-15
PE20040866A1 (es) 2004-11-26
ZA200500768B (en) 2006-07-26
IS7674A (is) 2005-01-27
ECSP055588A (es) 2005-04-18
BR0313378A (pt) 2005-07-12
EP1539715A1 (fr) 2005-06-15
GT200300169A (es) 2004-05-12

Similar Documents

Publication Publication Date Title
MA28746B1 (fr) Dérivés de quinazoline-4-yl-pipéridine et cinnoline-4-yl-pipéridine servant d'inhibiteurs de PDE10 pour le traitement de troubles du SNC
MA26739A1 (fr) Sel mutuel d'amlodipine et d'atorvastatine, procede pour sa preparation et compositions pharmaceutiques les contenant
MA27675A1 (fr) Derives de piperazine et leur utilisation dans le traitement de maladies neurologiques et psychiatriques
TNSN07248A1 (fr) Derive de pyrrolidyle de composes heteroaromatiques servant d'inhibiteurs de phosphodiesterases
TNSN07258A1 (fr) Derives de quinoleine heteroaromatiques et leur utilisation comme inhibiteurs de pde10
MA27582A1 (fr) Derives benzazepine pour le traitement de troubles neurologiques
BR9712086A (pt) Inibidores1,4-heterocìclicos de metaloproteinases
TNSN00092A1 (fr) Composes nouveaux antagonistes de npy, procede pour leur preparation et compositions pharmaceutiques les contenant
PH27592A (en) Imidazolyl-alkenoic acids and its method of use
EA200100774A1 (ru) Гетероциклические производные с функциональными группами (варианты), фармацевтическая композиция и комбинация, способ модулирования активности рецептора хемокина (варианты), способ профилактики инфицирования вич и лечения инфекции вич, замедления проявления спид и лечения спид, способ лечения воспалительных процессов
MA27668A1 (fr) 2,4-di(phenylamino) pyrimidines utilisees pour traiter des maladies neoplasiques, des troubles inflammatoires et des troubles du systeme immunitaire
MA26702A1 (fr) Compositions pharmaceutiques pour le traitement de la migraine, et procede pour leur preparation
MA27097A1 (fr) Aza-arylpiperazines
EA200500172A1 (ru) Азабициклопроизводные в качестве антагонистов мускариновых рецепторов
FR2738151B1 (fr) Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers
TNSN05035A1 (fr) Formes cristallines de [4-carbamoyl-1-(3-fluorobenzyl)-2, 7-dihydroxy-7-methyloctyl]-amide d'acide quinoxaline-2-carboxylique
TNSN98158A1 (fr) Associations pharmaceutiques d'amlodipine et d'une statine, et procede pour leur preparation
BR0016687A (pt) Pirrolidinas que inibem a pde especìfica do ampc
TNSN00106A1 (fr) Composition pharmaceutique nouvelle comprenant un inhibiteur de nos, et procede pour sa preparation
TNSN99056A1 (fr) Composes azabicycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
BR9503572A (pt) Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença
EA200501593A1 (ru) Азабициклические производные в качестве антагонистов мускаринового рецептора
DE69925270D1 (de) Mittel zur linderung von juckreiz, enthaltend pgd2- antagonisten
MY133845A (en) Il-8 receptor antagonists
BR9807085A (pt) Antagonistas de receptor de il-8